News & Events

Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress

CAMBRIDGE, Mass. (May 24, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.

Details of the presentations are as follows:

Abstract Number: EP841

Title: DISC-B, a selective matriptase-2 inhibitor, elicited robust increase in hepcidin-25 and reduction in serum iron in cynomolgus monkeys

Session: Iron metabolism, deficiency and overload

The e-poster presentation will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021. The abstract is currently available online on EHA2021 Virtual Congress Platform.

About Disc Medicine

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. We are committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic diseases. For more information, please visit www.discmedicine.com.

Media Contacts:

Sarah Ellinwood
sellinwood@vergescientific.com
202.930.4762

More News

Disc Medicine Announces $90 Millio...

Proceeds will be used to advance multiple programs in Disc’s hematology pipeline into phase 2 development Financing led by OrbiMed and includes...


read more

Disc Medicine Appoints Will Savage...

Company welcomes Dr. Hua Yang, PhD, as VP, Nonclinical Development and Clinical Pharmacology and Sarah Tuller, JD as VP, Regulatory Affairs CAMBRIDGE,...


read more

Disc Medicine Initiates Phase 1 Cl...

DISC-0974 is an investigational monoclonal antibody that utilizes a novel mechanism of action to suppress hepcidin, the master regulator of iron metabolism...


read more

Disc Medicine Expands Hematology P...

Clinical-Stage Program is Positioned to Enter Phase 2 Study in Erythropoietic Protoporphyria (EPP) CAMBRIDGE, Mass. (May 27, 2021) – Disc Medicine, Inc. announced...


read more

Disc Medicine to Present at the Je...

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious...


read more

Disc Medicine Appoints William Whi...

CAMBRIDGE, Mass. (January 13th, 2021) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine to Present at the Vi...

CAMBRIDGE, Mass. (December 2, 2020) – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine to Present at the Pi...

CAMBRIDGE, Mass. (November 23, 2020) – Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for...


read more

Disc Medicine Expands Scientific A...

Tomas Ganz, MD, PhD and Elizabeta Nemeth, PhD to Join Disc Medicine Scientific Advisory Board Cambridge, Mass. – October 13, 2020 –...


read more

Disc Medicine to Present at Citi&#...

Cambridge, Mass. – September 8, 2020 – Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates...


read more

Disc Medicine Expands Leadership T...

Jonathan Yu Named Senior Vice President of Corporate Strategy William Savage, MD, PhD Appointed Vice President of Clinical Development Cambridge, Mass. –...


read more

John Quisel, JD, PhD Joins Disc Me...

Co-founder and Interim CEO Brian MacDonald to Serve as Senior Advisor and Director Cambridge, Mass. – January 28, 2020 – Disc Medicine,...


read more

Disc Medicine Completes $50 Millio...

Cambridge, Mass. – October 29, 2019 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that...


read more

Disc Medicine Expands Pipeline Foc...

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicine,...


read more

Introducing Disc Medicine, a New H...

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions...


read more